India's rare disease policy sets a Rs. 50 lakh ceiling. Roche's Risdiplam costs Rs. 72 lakhs a year. A generic alternative exists at a fraction of the price, but is tied up in patent litigation. Amids ...
Put the Constitution First
Support bold, independent legal journalism with plans starting at just ₹1,770. Student subscriptions available at ₹590.